China Regenerative Medicine International Ltd
08158
Company Profile
Business description
China Regenerative Medicine International Ltd is an investment holding company engaged in the provision of healthcare products and services. Its reportable segments are Aesthetic medical and beauty services and Medical services. The vast majority of the company's revenue is derived from its Aesthetic medical and beauty services segment. Geographically, the People's Republic of China accounts for the majority of the revenue. It also has a presence in Hong Kong.
Contact
132 Nathan Road
Suite 2310-2318, Miramar Tower
Tsim Sha Tsui
Kowloon
HKGT: +852 39189000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
24
Stocks News & Analysis
stocks
Perplexing buyback from overvalued ASX share
Earnings continue to grow but investor expectations are too high.
stocks
Most popular shares in SMSFs
With data showing the continued rise of SMSFs, we explore the top stock picks of individual investors
stocks
Will China strong arm BHP into lower iron ore prices?
Allegations that the Chinese government told steel mills to stop buying from BHP shake markets.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,208.50 | 9.00 | -0.10% |
| CAC 40 | 7,898.18 | 36.08 | -0.45% |
| DAX 40 | 24,142.95 | 244.98 | -1.00% |
| Dow JONES (US) | 45,534.48 | 533.10 | -1.16% |
| FTSE 100 | 9,423.51 | 19.36 | -0.21% |
| HKSE | 25,441.35 | 448.13 | -1.73% |
| NASDAQ | 22,278.76 | 415.85 | -1.83% |
| Nikkei 225 | 46,847.32 | 1,733.12 | -3.57% |
| NZX 50 Index | 13,276.99 | 74.93 | -0.56% |
| S&P 500 | 6,570.22 | 84.50 | -1.27% |
| S&P/ASX 200 | 8,899.40 | 10.30 | -0.12% |
| SSE Composite Index | 3,865.23 | 24.27 | -0.62% |